Eagle Pharmaceuticals Inc (NASDAQ:EGRX) major shareholder Proquest Investments Iv, L.P. sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, March 20th. The shares were sold at an average price of $82.06, for a total transaction of $8,206,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Proquest Investments Iv, L.P. also recently made the following trade(s):

  • On Wednesday, January 4th, Proquest Investments Iv, L.P. sold 65,114 shares of Eagle Pharmaceuticals stock. The shares were sold at an average price of $85.16, for a total transaction of $5,545,108.24.

Shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) traded up 2.57% during midday trading on Monday, reaching $83.36. 352,494 shares of the company were exchanged. Eagle Pharmaceuticals Inc has a 12-month low of $33.02 and a 12-month high of $87.78. The stock has a market capitalization of $1.28 billion, a P/E ratio of 16.81 and a beta of 1.54. The company has a 50 day moving average price of $74.32 and a 200-day moving average price of $71.27.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its earnings results on Wednesday, March 1st. The specialty pharmaceutical company reported $3.52 earnings per share for the quarter, topping analysts’ consensus estimates of $2.82 by $0.70. Eagle Pharmaceuticals had a return on equity of 25.63% and a net margin of 20.06%. The business had revenue of $81.10 million for the quarter, compared to analyst estimates of $86.13 million. During the same quarter last year, the firm posted $0.08 earnings per share. The business’s revenue was up 345.6% compared to the same quarter last year. On average, analysts forecast that Eagle Pharmaceuticals Inc will post $3.79 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Your IP Address:

A number of hedge funds have recently added to or reduced their stakes in EGRX. Thrivent Financial for Lutherans raised its stake in Eagle Pharmaceuticals by 1.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $333,000 after buying an additional 60 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in Eagle Pharmaceuticals by 2.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 5,305 shares of the specialty pharmaceutical company’s stock worth $421,000 after buying an additional 150 shares during the last quarter. New York State Teachers Retirement System raised its stake in Eagle Pharmaceuticals by 2.0% in the fourth quarter. New York State Teachers Retirement System now owns 9,957 shares of the specialty pharmaceutical company’s stock worth $790,000 after buying an additional 200 shares during the last quarter. Comerica Bank raised its stake in Eagle Pharmaceuticals by 5.2% in the fourth quarter. Comerica Bank now owns 8,445 shares of the specialty pharmaceutical company’s stock worth $585,000 after buying an additional 415 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in Eagle Pharmaceuticals by 3.5% in the second quarter. Royal Bank of Canada now owns 12,351 shares of the specialty pharmaceutical company’s stock worth $479,000 after buying an additional 417 shares during the last quarter.

A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, January 16th. Mizuho restated an “underperform” rating and issued a $66.00 price objective on shares of Eagle Pharmaceuticals in a research report on Friday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $86.00 price objective on shares of Eagle Pharmaceuticals in a research report on Thursday, March 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $84.80.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

5 Day Chart for NASDAQ:EGRX

Receive News & Ratings for Eagle Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.